Anything is
Druggable
with Quantum Accuracy
They support us:
Qubit Pharmaceuticals brings unparalleled accuracy and precision to drug discovery and design, using quantum physics to develop life-changing treatments for major diseases.
No target
is undruggable
Our proprietary technologies, the fruit of over 30 years of research, make it possible to develop novel drug candidates and innovative modes of action against targets previously considered too complex.
Atlas
Our ultra-high resolution drug design platform, Atlas, enables drug hunters to discover, optimize & validate drug candidates and carry out complex computations at scale, on any hardware, whether on-premises or on the cloud.
polarizable force fields
State of the art last generation models, such as AMOEBA, reaching chemical accuracy included in ATLAS.
Sirius
Cutting-edge AI & Machine Learning solutions for efficient generative and predictive modeling of small molecules.
TINKER-HP
Fastest and most scalable Molecular Dynamics Software for polarizable force fields, accelerating AMOEBA calculations by a factor >100,000x.
Hyperion
Proprietary Quantum Simulation Platform. Development of next generation algorithms for quantum chemistry & drug discovery.
Gaia
Gaia is our 200 GPU supercomputer, created in collaboration with global leader Nvidia.
By marrying the best hardware technology to cutting-edge software, Atlas is able to carry out computations at scale with quantum accuracy to discover new drugs.
1000+
nanoseconds
1000ns of MD simulation per day with polarizable force fields
30+
qubits
Hybrid HPC-QC ready for computations over 30 qubits
Behind every target deemed too complex is a real patient with unmet needs.
We are developing novel drugs to cure life-threatening diseases, with a primary focus on oncology, inflammation and pandemic response.
We have multiple fully owned & partnered programs in discovery and are pursuing a broad pipeline of additional targets.
We actively shift the paradigm in drug discovery from drug hunting to drug farming.
Robert Marino, PhD
CEO Qubit Pharmaceuticals
Project pipeline
TARGET / Pathway
therapeutics areas
Target/ MOA characterisation
Hit to lead
Lead to pre-candidate
partner
KAT6A
Oncology
IL4R
Inflammation
mRas
Oncology
TREX1
Sting Pathway
Undisclosed GPCR
Multiple
RNA - RBP Platform
Oncology & Inflammation
Antivirals
Platform
Multiple targets in partnerships
Various
+ 16 additional drug discovery programs under evaluation
Project pipeline
IL4R
Inflammation
Target / MOA
characterisation
Hit to lead
Lead to
pre-candidate
USP7
Oncology
Target / MOA
characterisation
Hit to lead
Lead to
pre-candidate
MRas
Ras driven oncology
Target / MOA
characterisation
Hit to lead
Lead to
pre-candidate
KAT6A
Oncology
Target / MOA
characterisation
Hit to lead
Lead to
pre-candidate
Undisclosed Metalloenzyme
Oncology
Target / MOA
characterisation
Hit to lead
Lead to
pre-candidate
Undisclosed GPCR
Oncology & Inflammation
Target / MOA
characterisation
Hit to lead
Lead to
pre-candidate
+16 additional discovery programs
Various
Various
Target / MOA
characterisation
Hit to lead
Lead to
pre-candidate
supercomputer
drug discovery programs brought to preclinicals and clinical stages by team members during their careers.
PhDs
publications
raised
Meet
our
founders
Expert in High Performance Computing, numerical methods and sampling. Lead developer Tinker-HP. Atos Fourier Prize Laureate.
Expert in drug discovery. 8 patents. 1 program at clinical stage.
Expert in quantum chemistry and High Performance Computional. Atos Fourier Prize and ERC Synergy Laureate. Scientific leader Tinker-HP. Fellow of the Royal Society of Chemistry (London).
Expert in structural biology and biomolecular simulation. Fellow of AAAS and past Gordon conference chairperson. Lead developer Tinker and AMOEBA.
Professor of Biomedical Engineering. Expert in multi-scale modelling of proteins and nucleic acids. Lead developer Amoeba.
One team, one mission, infinite ambition
Based in Paris and Boston, our team of over 40 people is made up of over 12 different nationalities. We are a diverse mix of various expertise, backgrounds and perspectives. Our mission? To have a real positive impact on drug design and discovery through computational technology and create treatments that transform lives.
Developing better drugs, together
Drug discovery is very much a team effort. We are always looking to explore ways to develop novel treatments to cure major diseases.
We’re looking for partners to co-develop our drug discovery programs. We’re also keen to evaluate the possibility to jointly accelerate existing drug discovery programs or unlock complex targets with the support of Atlas and our drug discovery team.
We’re interested in expanding our portfolio in inflammation and oncology. We’re seeking for novel targets with ideally a crystal structure available, PDX and/or patient lines available and a lab stage assay. Prior demonstration of druggability is not mandatory.
Interested in partnering with us?
News & Research
October 7, 2024
Blog
Joint research paper with Pasqal: How Analog Quantum Computing is Transforming Drug Discovery
.png)
September 12, 2024
LinkedIn Blog
Paper on Spike Protein Dynamics among the 2024 Chemical Science HOT Articles Collection
%20(1).png)
August 13, 2024
Press Release
Qubit Pharmaceuticals nominated for "Best Startup 2024" award by Prix Galien USA
July 10, 2024
Press Release
Major breakthrough in quantum algorithms: Qubit Pharma and Sorbonne University drastically reduce the number of qubits needed to simulate molecules
.png)
June 6, 2024
Press Release
Qubit Pharmaceuticals selected as one of the 100 Technology Pioneers 2024 by the World Economic Forum
January 30, 2024
Press Release
High-Performance Computing, simulations and AI: Qubit Pharmaceuticals, Institut Curie and the University of Bordeaux Join Forces to Advance the Development of Novel Cancer Therapies
.png)
December 13, 2023
Press Release
Qubit Pharmaceuticals strengthens its commitment to DistriQ - Quantum Innovation Zone by partnering with the PINQ² platform in order to accelerate pharmaceutical research through quantum computing
December 6, 2023
Press Release
Qubit Pharmaceuticals and Sorbonne University achieve a major scientific breakthrough by simulating quantum calculations at more than 40 qubits on conventional computers
.png)
November 16, 2023
Qubit Pharmaceuticals Invests €4.5M in Innovative RNA Therapeutics Platform!
November 9, 2023
Advancing Quantum Chemistry with Quantum Computing: A Pioneering Approach to Sparse Quantum State Preparation for Strongly Correlated Systems
November 7, 2023
Qubit Pharmaceuticals honored to announce the arrival of renowned Quantum Computing researcher Dr. Alberto Peruzzo as R&D Lead in Quantum Computing
September 28, 2023
Revolutionizing Drug Discovery: Quantum Computing Meets Solvent Configuration Prediction
September 26, 2023
French start-ups Pasqal and Qubit Pharmaceuticals join with Unitary Fund to win Wellcome Trust's "Quantum for Bio" program
June 12, 2023
Qubit Pharmaceuticals joins the Acuité Québec Consortium to innovate in drug design
May 22, 2023
"The purpose of Qubit Pharmaceuticals is to treat patients."
May 12, 2023
Qubit Pharmaceuticals is joining the partner ecosystem of Eviden , an Atos business!
March 31, 2023
Qubit Pharmaceuticals is a laureate of the very first class of the French Tech #Health20!
March 14, 2023
Thanks a lot France Digitale and XAnge for identifying us as a future digital champion!
January 24, 2023
A big step forward for quantum computer-assisted #drugdiscovery at Qubit Pharmaceuticals!
November 30, 2022
Nvidia
Qubit Pharmaceuticals Accelerates Drug Discovery With Hybrid Quantum Computing
November 29, 2022
HPC Innovation Excellence Award
November 7, 2022
We are part of Fujitsu Accelerator Program for CaaS !
March 31, 2023
Qubit Pharmaceuticals is a laureate of the very first class of the French Tech #Health20!
©2023 Qubit Pharmaceuticals.
All Rights Reserved.
Disclaimer: Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or EISMEA. Neither the European Union nor the granting authority can be held responsible for them.
Legal notice